- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innate Pharma (IPH)
Assess today's live Innate Pharma (IPH) share price, performance and insights using our live Paris: IPH stock exchange data.
Analyse the historical data and Innate Pharma share price performance charts on this page. Our technical summary section provides analysis on Innate Pharma share price buy/sell indicators using real-time data (or discuss the Innate Pharma (IPH) stock price today with other investors in the Innate Pharma EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA IPH share price (ISIN: FR0010331421) to enhance your trading decisions with our free investment tools and resources.
What Is the Innate Pharma Share Price Today?
The Innate Pharma share price today is 1.1000.
What Is the Stock Symbol for Innate Pharma
The stock symbol (or 'ticker') for Innate Pharma is "IPH."
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris stock exchange.
Is Innate Pharma a Good Stock to Buy?
Determining whether Innate Pharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Innate Pharma share price performance charts on this page. Our technical summary section provides analysis on Innate Pharma share price buy/sell indicators using real-time data (or discuss the Innate Pharma (IPH) stock price today with other investors in the Innate Pharma EPA share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current EPA IPH share price (ISIN: FR0010331421) to enhance your trading decisions with our free investment tools and resources.
What Is the Innate Pharma Share Price Today?
The Innate Pharma share price today is 1.1000.
What Is the Stock Symbol for Innate Pharma
The stock symbol (or 'ticker') for Innate Pharma is "IPH."
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris stock exchange.
Is Innate Pharma a Good Stock to Buy?
Determining whether Innate Pharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in EUR
1.1000
+0.0160(+1.48%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0720
1.1320
52 wk Range
1.0300
2.1000
IPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.07201.1320
52 wk Range
1.03002.1000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.3500
Upside
+386.36%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Form 13G Innate Pharma SA For: 4 March
- Investing.com
- Form 6K Innate Pharma For: 18 February
- Investing.com
- Form 6K Innate Pharma For: 19 March
- Investing.com
- Form 6K Innate Pharma For: 19 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma Earnings Call Summary for Q3/2025
- Innate Pharma reported a €56.4 million cash position with runway through Q3 2026, though stock fell 2.29% following the earnings announcement lacking detailed financial metrics.
- The company is advancing key assets including IPH4502 and Monalizumab, with anticipated data readouts in H1 and H2 2026 respectively.
- CEO Jonathan Dickinson highlighted Lacutamab as a 'game-changer' with potential accelerated approval in 2027 and strategic positioning in the CTCL market.
- Executives expressed confidence in manufacturing capabilities and commercial readiness during Q&A, emphasizing efforts to position Lacutamab within NCCN guidelines.
Last Updated: 13/11/2025, 14:04
Read Full TranscriptCompare IPH to Peers and Sector
Metrics to compare | IPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −2.2x | −0.4x | |
PEG Ratio | −0.21 | 0.01 | 0.00 | |
Price/Book | −4.8x | 1.5x | 2.6x | |
Price / LTM Sales | 11.4x | 8.9x | 3.1x | |
Upside (Analyst Target) | 386.4% | 182.6% | 58.6% | |
Fair Value Upside | Unlock | 25.8% | 8.2% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.3500
(+386.36% Upside)
Earnings
Latest Release
26/03/2026
EPS / Forecast
-0.31 / -0.12
Revenue / Forecast
4.15M / 2.15M
People Also Watch
FAQ
What Is the Innate Pharma (IPH) Share Price Today?
The Innate Pharma stock price today is 1.1000 EUR.
What Stock Exchange Does Innate Pharma (IPH) Trade On?
Innate Pharma is listed and trades on the Paris Stock Exchange.
What Is the Ticker (Stock Symbol) for Innate Pharma?
The stock symbol (also called a 'ticker') for Innate Pharma is "IPH."
What Is the Current Innate Pharma Market Cap?
As of today, Innate Pharma market cap is 103.1000M EUR.
What Is Innate Pharma's (IPH) Earnings Per Share (TTM)?
The Innate Pharma EPS is currently -0.5500 (Trailing Twelve Months).
When Is the Next Innate Pharma Earnings Date?
Innate Pharma's next earnings report will be released on 13/05/2026.
Is IPH a Buy or Sell From a Technical Analyst Perspective?
Based on today's Innate Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Innate Pharma Stock Split?
Innate Pharma has split 0 times. (See the IPH stock split history page for full effective split date and price information.)
How Many Employees Does Innate Pharma Have?
Innate Pharma has 174 employees.
What is the current trading status of Innate Pharma (IPH)?
As of 28/03/2026, Innate Pharma (IPH) is trading at a price of 1.1000 EUR, with a previous close of 1.0840 EUR. The stock has fluctuated within a day range of 1.0720 EUR to 1.1320 EUR, while its 52-week range spans from 1.0300 EUR to 2.1000 EUR.
What Is Innate Pharma (IPH) Price Target According to Analysts?
The average 12-month price target for Innate Pharma is 5.3500 EUR, with a high estimate of 6.2 EUR and a low estimate of 4.5 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +386.36% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.